Publications by authors named "Sellvakumaram Paramasivam"
Germline PALB2 Variants and PARP Inhibitors in Endometrial Cancer.
J Natl Compr Canc Netw
November 2021
Article Synopsis
- A case study describes a woman with recurrent endometrial carcinoma who had a rare genetic deletion (PALB2), leading to the use of the PARP inhibitor olaparib, which initially helped but was followed by disease progression.
- There is a call for more research on resistance to PARP inhibitors and whether risk-reducing hysterectomy could be beneficial for female PALB2 variant carriers, beyond current focus on breast and ovarian cancer.
Background: The value of hospital registries for describing treatment and survival outcomes for vulval cancer was investigated. Hospital registry data from four major public hospitals in 1984-2016 were used because population-based data lacked required treatment and outcomes data. Unlike population registries, the hospital registries had recorded FIGO stage, grade and treatment.
View Article and Find Full Text PDF